Key Takeaways
- Dr. John H. Krystal, MD, professor of psychiatry at Yale, will receive the 2026 Connecticut Medal of Technology for his seminal discovery of ketamine’s rapid antidepressant effects, which led to the first mechanistically novel FDA‑approved antidepressant in over half a century.
- His work linked glutamate signaling, synaptic restoration, and mTORC1 pathways to antidepressant action, and extended to breakthroughs in PTSD, alcohol use disorder, and schizophrenia research.
- The RTX Technology Research Center (RTRC) is co‑honored for more than 95 years of innovations in commercial aviation and defense, underscoring Connecticut’s strength in both biomedical and aerospace technology.
- The Connecticut Medal of Technology, modeled after the National Medal of Technology and Innovation, recognizes contributions that advance the state’s economic, environmental, and social well‑being while inspiring future technical talent.
Award Announcement and Ceremony Details
John H. Krystal, MD, the Robert L. McNeil, Jr. Professor of Translational Research and chair of the Yale Department of Psychiatry, has been selected to receive the 2026 Connecticut Medal of Technology. He will accept the honor alongside representatives from the RTX Technology Research Center (RTRC) at a ceremony arranged by the Connecticut Academy of Science and Engineering (CASE). The formal presentation will occur during CASE’s Annual Dinner on May 19, 2026. The award celebrates individuals and organizations whose technological innovations have substantially benefited Connecticut and the nation.
Dr. John H. Krystal’s Contributions to Psychiatry
Krystal is recognized specifically “for the discovery of the rapid antidepressant actions of ketamine, the most important clinical advance in psychiatry in the current era, leading to the development of esketamine, the first mechanistically novel FDA‑approved antidepressant in over 50 years.” His research transformed the treatment landscape for major depressive disorder by demonstrating that a single sub‑anesthetic dose of ketamine can produce antidepressant effects within hours, a stark contrast to the weeks‑long latency of traditional antidepressants.
Mechanisms of Ketamine’s Antidepressant Action
Through a multidisciplinary approach combining psychopharmacology, neuroimaging, molecular genetics, and computational neuroscience, Krystal and his collaborators elucidated several biological mechanisms underlying ketamine’s efficacy. They showed enhanced glutamate release measured by ^13C‑magnetic resonance spectroscopy, restoration of cortical functional connectivity deficits via functional MRI, and recovery of synaptic density assessed with positron emission tomography. Further work identified that sustaining these effects involves mTORC1 pathway modulation and glycine‑site NMDA‑receptor regulation, offering novel targets for next‑generation antidepressants.
Broader Research on PTSD, Alcohol Use Disorder, and Schizophrenia
Beyond depression, Krystal has made pivotal contributions to the neurobiology of post‑traumatic stress disorder (PTSD), alcohol use disorder, and schizophrenia. In the early 1990s he identified the first biological mechanism linked to PTSD, laying groundwork for biomarker development. More recently, he co‑founded the National PTSD Brain Bank and co‑led the first well‑powered transcriptomic study of PTSD, advancing understanding of gene expression patterns in trauma‑related pathology. His schizophrenia research clarified cortical mechanisms that underlie symptoms and predicted the emergence of non‑dopaminergic therapeutics; the first such drug, Cobenfy, gained FDA approval in 2024.
Academic Background and Leadership Roles
Krystal earned a Bachelor of Arts in behavioral sciences from the University of Chicago (1980), an MD from Yale School of Medicine (1984), and completed psychiatry residency at Yale (1988). He serves as chief of psychiatry for the Yale New Haven Health System and co‑leads the Yale Center for Clinical Investigation. Additionally, he directs the Clinical Neuroscience Division of the National Center for PTSD (VA) and co‑directs the NIAAA Center for the Translational Neuroscience of Alcohol, reflecting his expansive influence across clinical, translational, and administrative domains.
Innovation and Entrepreneurial Activities
As a co‑inventor on multiple patents licensed to pharmaceutical and digital health companies, Krystal bridges basic discovery and commercial application. He has contributed to the founding of two pharmaceutical enterprises—Biohaven Pharmaceuticals and Freedom Biosciences—demonstrating his commitment to translating scientific insights into tangible therapies that reach patients.
Recognition and Awards
Krystal’s achievements have been repeatedly honored by leading scientific bodies. Recent accolades include the Sarnat Prize of the National Academy of Medicine (2023), the ACNP Barbara Fish Memorial Award (2023), the American Psychiatric Association Nasarallah Family Neuroscience Award (2023), the British Pharmacologic Society’s Sir John Gaddam Memorial Lecture and Medal (2022), and the Gold Medal Award of the Society of Biological Psychiatry (2018). He is a member of the U.S. National Academy of Medicine and the Connecticut Academy of Science and Engineering, a fellow of the American Association for the Advancement of Science, and has served in leadership roles such as past co‑chair of the Neuroscience Forum of the U.S. National Academies and chair of the NIMH Board of Scientific Counselors.
Role as Editor and Leadership in Scientific Societies
Since 2006, Krystal has served as editor of Biological Psychiatry, overseeing the launch of sister journals BP: Cognitive Neuroscience and Neuroimaging (2015) and BP: Global Open Science (2020). He has also held past presidencies of the American College of Neuropsychopharmacology (ACNP) and the International College of Neuropsychopharmacology (CINP), shaping the direction of neuropsychopharmacology research and fostering international collaboration.
RTX Technology Research Center (RTRC) Honoree Profile
The RTX Technology Research Center, Connecticut’s premier R&D hub for RTX and its business units—including Pratt & Whitney and Collins Aerospace—receives the medal for “developing era‑defining breakthroughs in commercial aviation and defense for over 95 years.” Throughout its history, RTRC scientists and engineers have tackled the sector’s most demanding challenges, continually pushing technological boundaries to enhance connectivity, safety, and performance worldwide.
Impact of the Connecticut Medal of Technology
Modeled after the National Medal of Technology and Innovation, the Connecticut Medal of Technology is awarded by the State of Connecticut through the Office of the Governor, with assistance from CASE. It honors individuals, teams, and organizations whose technological innovations advance the state’s economic, environmental, and social well‑being while fostering a skilled technical workforce. By spotlighting transformative contributions like those of Krystal and RTRC, the award aims to inspire future generations to pursue careers in science, engineering, and technology, ensuring Connecticut remains at the forefront of global innovation.
Conclusion
The 2026 Connecticut Medal of Technology celebrates a dual legacy of biomedical breakthroughs and aerospace excellence. Dr. John H. Krystal’s pioneering work on ketamine’s rapid antidepressant mechanisms has reshaped psychiatric treatment and opened new avenues for understanding PTSD, addiction, and schizophrenia. Concurrently, the RTX Technology Research Center’s nearly century‑long record of aviation and defense innovations underscores Connecticut’s strength in high‑impact engineering. Together, their recognition highlights the state’s capacity to foster world‑class scientific discovery and technological advancement, reinforcing a vision of sustained economic growth and societal benefit.